Most-cited articles · 2022

The 50 most-cited articles in Radiotherapy and Oncology, 2022

Ranked by OpenAlex citation count on 29 October 2026, out of 584 eligible articles Radiotherapy and Oncology published in 2022. Ranks are frozen; this page will not change. Number one, with 135 citations: FLASH with carbon ions: Tumor control, normal tissue sparing, and distal metastasis in a mouse osteosarcoma model.

Cohort
584 articles
Listed
Top 50 (8.6%)
Open access
33 of 50
Snapshot
2026-10-29

The most-cited articles from Radiotherapy and Oncology in 2022 cluster around three themes: ultra-high dose rate FLASH radiotherapy, clinical guidelines from ESTRO and its advisory committees, and studies of radiation-related lymphopenia and hypoxia. The top paper, by Walter Tinganelli, Uli Andreas Weber, Anggraeini Puspitasari and colleagues, examined FLASH with carbon ions in a mouse osteosarcoma model and received 135 citations. It is followed closely by a pencil beam scanning proton FLASH study in a mouse model with 133 citations, and by an ESTRO-ACROP guideline on surface guided radiation therapy with 109 citations.

For readers, the list offers a citation-based snapshot of the work that drew the most attention in the journal that year. It spans preclinical FLASH experiments, consensus and guideline documents, trial reports such as the RAPIDO study, and reviews on topics including variable proton relative biological effectiveness and lymphocyte-sparing dose constraints. The ranking reflects citation counts recorded by OpenAlex out of 584 eligible articles and does not by itself indicate study quality or clinical importance.

Introduction written from the titles and abstracts on this list. Every figure below is the source.

Ask about these papers

Grounded in this list only, with sources.

3 of 3 free questions left today, no account needed
  1. 1
    top 0.2%

    FLASH with carbon ions: Tumor control, normal tissue sparing, and distal metastasis in a mouse osteosarcoma model

    Walter Tinganelli, Uli Andreas Weber, Anggraeini Puspitasari, Palma Simoniello, Amir Abdollahi and 6 more

    135 citationsdoi:10.1016/j.radonc.2022.05.003OpenAlex

  2. 2
    top 0.4%

    Pencil beam scanning proton FLASH maintains tumor control while normal tissue damage is reduced in a mouse model

    Brita Singers Sørensen, Mateusz Krzysztof Sitarz, Christina Ankjærgaard, Jacob Johansen, Claus Erik Andersen and 3 more

    133 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.05.014OpenAlex

    Show abstract

    Purpose Preclinical studies indicate a normal tissue sparing effect when ultra-high dose rate (FLASH) radiation is used, while tumor response is maintained. This differential response has promising perspectives for improved clinical outcome. This study investigates tumor control and normal tissue toxicity of pencil beam scanning (PBS) proton FLASH in a mouse model. Methods and materials Tumor bearing hind limbs of non-anaesthetized CDF1 mice were irradiated in a single fraction with a PBS proton beam using either conventional (CONV) dose rate (0.33–0.63 Gy/s field dose rate, 244 MeV) or FLASH (71–89 Gy/s field dose rate, 250 MeV). 162 mice with a C3H mouse mammary carcinoma subcutaneously implanted in the foot were irradiated with physical doses of 40–60 Gy (8–14 mice per dose point). The endpoints were tumor control (TC) assessed as no recurrent tumor at 90 days after treatment, the level of acute moist desquamation (MD) to the skin of the foot within 25 days post irradiation, and radiation induced fibrosis (RIF) within 24 weeks post irradiation. Results TCD 50 (dose for 50% tumor…

  3. 3
    top 0.6%

    ESTRO-ACROP guideline on surface guided radiation therapy

    P. Freislederer, Vania Batista, Michel Öllers, Martin Buschmann, Elisabeth Steiner and 10 more

    109 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.05.026OpenAlex

    Show abstract

    Surface guidance systems enable patient positioning and motion monitoring without using ionising radiation. Surface Guided Radiation Therapy (SGRT) has therefore been widely adopted in radiation therapy in recent years, but guidelines on workflows and specific quality assurance (QA) are lacking. This ESTRO-ACROP guideline aims to give recommendations concerning SGRT roles and responsibilities and highlights common challenges and potential errors. Comprehensive guidelines for procurement, acceptance, commissioning, and QA of SGRT systems installed on computed tomography (CT) simulators, C-arm linacs, closed-bore linacs, and particle therapy treatment systems are presented that will help move to a consensus among SGRT users and facilitate a safe and efficient implementation and clinical application of SGRT.

  4. 4
    top 0.7%

    ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases

    Joanne M. van der Velden, Jonas Willmann, Mateusz Jacek Spalek, Eva Oldenburger, Stephanie Lea Brown and 5 more

    107 citationsOpen accessdoi:10.1016/j.radonc.2022.05.024OpenAlex

  5. 5
    top 0.9%

    GEC-ESTRO ACROP prostate brachytherapy guidelines

    Ann M. Henry, Bradley Rumwell Pieters, Frank André Siebert, Peter Hoskin

    107 citationsOpen access (OTHER-OA)doi:10.1016/j.radonc.2021.12.047OpenAlex

  6. 6
    top 1.1%

    Online adaptive radiotherapy of urinary bladder cancer with full re-optimization to the anatomy of the day: Initial experience and dosimetric benefits

    Lina M. Åström, C.F. Behrens, Lucie Calmels, David Sjöström, Poul Flemming Geertsen and 4 more

    104 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.03.014OpenAlex

    Show abstract

    Background and purpose Online adaptive radiotherapy (oART) potentially reduces the dose to organs at risk (OARs) as the planning target volume (PTV) margins are reduced compared to a non-adaptive approach (non-ART). This study evaluates the feasibility and dosimetric impact of cone-beam computed tomography (CBCT)-guided oART of urinary bladder cancer for the first patients treated, using patient-specific margins. Materials and methods Sixteen consecutive patients with muscle-invasive bladder cancer received two or more (median = 23) fractions as oART, and remaining fractions as non-ART. The non-ART fractions were delivered with standard population-based margins, while reduced patient-specific margins based on intra-fractional variations extracted from 2-4 fractions were applied to the primary PTV (PTV-T) during the oART fractions. Target volume and coverage, and dose to OARs were compared between non-ART and oART plans, and the oART procedure time was recorded. Results In total, 297/512 fractions were delivered as oART with full re-optimization to the anatomy of the day. The median…

  7. 7
    top 1.2%

    Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus

    Thomas Zilli, Vérane Achard, Alan Dal Pra, Nina Schmidt-Hegemann, Barbara Alicja Jereczek‐Fossa and 21 more

    101 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.10.005OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: Oligometastatic prostate cancer is a new and emerging treatment field with only few prospective randomized studies published so far. Despite the lack of strong level I evidence, metastasis-directed therapies (MDT) are widely used in clinical practice, mainly based on retrospective and small phase 2 studies and with a large difference across centers. Pending results of ongoing prospective randomized trials, there is a clear need for more consistent treatment indications and radiotherapy practices. MATERIAL AND METHODS: A European Society for Radiotherapy and Oncology (ESTRO) Guidelines Committee consisting of radiation oncologists' experts in prostate cancer was asked to answer a dedicated questionnaire, including 41 questions on the main controversial issues with regard to oligometastatic prostate cancer. RESULTS: The panel achieved consensus on patient selection and routine use of prostate-specific membrane antigen positron emission tomography (PSMA PET) imaging as preferred staging and restaging imaging. MDT strategies are recommended in the de novo…

  8. 8
    top 1.4%

    Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer – The RAPIDO trial

    Esmée A. Dijkstra, Geke A.P. Hospers, Elma Meershoek‐Klein Kranenbarg, Joke Fleer, Annet G.H. Roodvoets and 13 more

    93 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.radonc.2022.04.013OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: The RAPIDO trial demonstrated a decrease in disease-related treatment failure (DrTF) and an increase in pathological complete responses (pCR) in locally advanced rectal cancer (LARC) patients receiving total neoadjuvant treatment (TNT) compared to conventional chemoradiotherapy. This study examines health-related quality of life (HRQL), bowel function, and late toxicity in patients in the trial. MATERIALS AND METHODS: Patients were randomized between short-course radiotherapy followed by pre-operative chemotherapy (EXP), or chemoradiotherapy and optional post-operative chemotherapy (STD). The STD group was divided into patients who did (STD+) and did not (STD-) receive post-operative chemotherapy. Three years after surgery patients received HRQL (EORTC QLQ-C30, QLQ-CR29 and QLQ-CIPN20) and LARS questionnaires. Patients who experienced a DrTF event before the toxicity assessments (6, 12, 24, or 36 months) were excluded from analyses. RESULTS: Of 574 eligible patients, 495 questionnaires were returned (86%) and 453 analyzed (79% completed within time limits).…

  9. 9
    top 1.6%

    Comparison of ultra-high versus conventional dose rate radiotherapy in a patient with cutaneous lymphoma

    Olivier Gaide, Fernanda Gabriela Herrera, Wendy Jeanneret Sozzi, Patrik Gonçalves Jorge, Rémy Kinj and 10 more

    93 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.radonc.2021.12.045OpenAlex

    Show abstract

    A patient with a cutaneous lymphoma was treated on the same day for 2 distinct tumors using a 15 Gy single electron dose given in a dose rate of 0.08 Gy/second versus 166 Gy/second. Comparing the two treatments, there was no difference for acute reactions, late effects at 2 years and tumor control.

  10. 10
    top 1.8%

    ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases

    Eva Oldenburger, Stephanie Lea Brown, Jonas Willmann, Joanne M. van der Velden, Mateusz Jacek Spalek and 5 more

    91 citationsOpen accessdoi:10.1016/j.radonc.2022.06.002OpenAlex

  11. 13
    top 2.3%

    Beam pulse structure and dose rate as determinants for the flash effect observed in zebrafish embryo

    Leonhard Karsch, Jörg Pawelke, Michael Brand, Stefan Hans, Katalin Hidéghety and 8 more

    71 citationsdoi:10.1016/j.radonc.2022.05.025OpenAlex

  12. 14
    top 2.4%

    Increased relative biological effectiveness and periventricular radiosensitivity in proton therapy of glioma patients

    Jan Eulitz, Esther G.C. Troost, Lauritz Klünder, Felix Raschke, Christian Hahn and 10 more

    67 citationsdoi:10.1016/j.radonc.2022.11.011OpenAlex

  13. 16
    top 2.8%
  14. 17
    top 3%

    A systematic review of clinical studies on variable proton Relative Biological Effectiveness (RBE)

    Tracy S. A. Underwood, Aimee L. McNamara, Ane Lindegaard Appelt, Joanne Haviland, Brita Singers Sørensen and 1 more

    64 citationsdoi:10.1016/j.radonc.2022.08.014OpenAlex

  15. 18
    top 3.1%

    Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [18F]FMISO PET/CT

    Stefan Welz, Frank Paulsen, Christina Pfannenberg, Matthias Reimold, Gerald Reischl and 6 more

    64 citationsOpen access (CC-BY-NC)doi:10.1016/j.radonc.2022.03.021OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: F]FMISO (dynFMISO) positron emission tomography (PET). The purpose was to confirm the prognostic value of hypoxia PET and assess feasibility, toxicity and efficacy of hypoxia-DE. MATERIALS AND METHODS: Patients with LASCCHN underwent baseline dynFMISO PET/CT. Hypoxic volumes (HV) were derived from dynFMISO data. Patients with hypoxic tumors (HV > 0) were randomized into standard radiotherapy (ST: 70Gy/35fx) or dose escalation (DE: 77Gy/35fx) to the HV. Patients with non-hypoxic tumors were treated with ST. After a minimum follow-up of 2 years feasibility, acute/late toxicity and local control (LC) were analyzed. RESULTS: The study was closed prematurely due to slow accrual. Between 2009 and 2017, 53 patients were enrolled, 39 (74%) had hypoxic tumors and were randomized into ST or DE. For non-hypoxic patients, 100% 5-year LC was observed compared to 74% in patients with hypoxic tumors (p = 0.039). The difference in 5-year LC between DE (16/19) and ST (10/17) was 25%, p = 0.150. No relevant differences related to acute and late toxicities between the groups…

  16. 19
    top 3.3%

    Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial

    Marie Overgaard, Hanne Melgaard Nielsen, Trine Tramm, Inger Højris, Trine Lønbo Grantzau and 3 more

    64 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.03.008OpenAlex

    Show abstract

    BACKGROUND: Between 1982 and 1990 the Danish Breast Cancer Cooperative Group (DBCG) conducted a randomized trial in high-risk pre- and postmenopausal (<70 years) breast cancer patients comparing mastectomy plus adjuvant systemic therapy alone versus the same treatment plus postoperative irradiation. AIM: To present a comprehensive analysis of the complete DBCG 82bc study with a 30-year long-term follow-up of the cancer therapeutic effect and survival, together with an additional focus on the potential long-term life-threatening morbidity related to cardiac irradiation and/or the risk of secondary cancer induction. METHODS: A total of 3083 patients with pathological stage II and stage III breast cancer were after mastectomy randomly assigned to receive adjuvant systemic therapy and postoperative irradiation to the chestwall and regional lymph nodes (1538 pts), or adjuvant systemic therapy alone (1545 pts). Pre- and menopausal patients (DBCG 82b) received 8-9 cycles of CMF with an interval of 4 weeks, whereas postmenopausal patients (DBCG 82c) received tamoxifen 30 mg daily for one…

  17. 20
    top 3.5%

    Comparing radiolytic production of H2O2 and development of Zebrafish embryos after ultra high dose rate exposure with electron and transmission proton beams

    Houda Kacem, S. Psoroulas, Gaël Boivin, Michael Folkerts, Veljko Grilj and 11 more

    62 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.07.011OpenAlex

    Show abstract

    The physico-chemical and biological response to conventional and UHDR electron and proton beams was investigated, along with conventional photons. The temporal structure and nature of the beam affected both, with electron beam at ≥1400 Gy/s and proton beam at 0.1 and 1260 Gy/s found to be isoefficient at sparing zebrafish embryos.

  18. 21
    top 3.6%

    Simulated computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR) for the treatment of locally advanced pancreatic cancer

    Joshua P. Schiff, Alex T. Price, H.B. Stowe, Eric Laugeman, Re-I Chin and 8 more

    60 citationsdoi:10.1016/j.radonc.2022.08.026OpenAlex

  19. 22
    top 3.8%

    Training, validation, and clinical implementation of a deep-learning segmentation model for radiotherapy of loco-regional breast cancer

    Sigrun Saur Almberg, Christoffer Lervåg, Jomar Frengen, Monica Eidem, Tatiana Mikhailovna Abramova and 5 more

    56 citationsdoi:10.1016/j.radonc.2022.05.018OpenAlex

  20. 23
    top 4%

    Magnetic resonance imaging (MRI) guided proton therapy: A review of the clinical challenges, potential benefits and pathway to implementation

    Trang Thanh Pham, Brendan Whelan, Bradley M. Oborn, Geoff P. Delaney, Shalini Kavita Vinod and 3 more

    56 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.radonc.2022.02.031OpenAlex

    Show abstract

    Proton therapy and MRI-Linacs are two of the most exciting and fast growing technologies in radiation oncology. With over 100 MRI-Linacs and 100 proton therapy centres either in operation or under construction, an integrated approach that brings together the excellent soft tissue imaging of MRI with the superior dose conformity of proton therapy is compelling. The promise of MRI-guided proton therapy has prompted multiple research studies and the building of two pre-clinical experimental systems, taking us closer to realisation of this technology. Patients who would benefit most are those whose cancers have substantial tumour motion or anatomical variation, and those who are currently unable to receive safe dose-escalation due to nearby critical structures. MRI-guided proton therapy could allow more patients with pancreatic cancer, central lung cancer and oligo-metastatic cancers in the upper abdomen (e.g. liver and adrenal) to safely receive escalated curative doses. Head and neck, lung, brain and cervix cancers, where treatment accuracy is affected by inter-fraction tumour changes…

  21. 24
    top 4.2%

    Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study

    Tiuri Ewout Kroese, Sebastian M. Christ, Peter S.N. van Rossum, Matthijs D. L. Burger, George S. Buijs and 7 more

    53 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.06.012OpenAlex

    Show abstract

    PURPOSE/OBJECTIVE: This multicenter study assessed the incidence and survival of patients with esophagogastric cancer and oligometastatic disease (OMD) in two tertiary referral cancer centers in The Netherlands and Switzerland. MATERIALS/METHODS: F-FDG-PET/CT). Control of the primary tumor was considered in patients who underwent primary tumor resection or definitive chemoradiotherapy without locoregional recurrence. Treatment of OMD was categorized into (1) systemic therapy, (2) local treatment (stereotactic body radiotherapy or metastasectomy), (3) local plus systemic therapy, or (4) best supportive care. The primary outcomes were overall survival (OS) and independent prognostic factors for OS. Independent prognostic factors for OS were analyzed using multivariable Cox proportional hazard models. RESULTS: In total, 830 patients with metastatic esophagogastric cancer were identified of whom 200 patients with de-novo OMD were included (24%). The majority of included patients had esophageal cancer (73%) with adenocarcinoma histology (79%) and metachronous OMD (52%). The primary tumor…

  22. 25
    top 4.3%

    Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study

    Jonas Willmann, Eugenia Vlaskou Badra, Selma Adilovic, Maiwand Ahmadsei, Sebastian M. Christ and 5 more

    51 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.radonc.2022.01.019OpenAlex

    Show abstract

    PURPOSE: To explore the prognostic value of the oligometastatic disease (OMD) states as proposed by the European Society for Radiotherapy and Oncology (ESTRO) European Organisation for Research and Treatment of Cancer (EORTC) classification system. MATERIALS AND METHODS: This retrospective single-institution study included patients with 1-5 extracranial metastases from any solid malignancy treated with SBRT to all metastases. OMD states were defined according to the ESTRO EORTC classification. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method. Discriminatory strength of the classification was assessed by Gönen & Heller's concordance probability estimate (CPE). Univariable and multivariable Cox regression models were used to assess predictors of OS and PFS. RESULTS: In total, 385 patients were included. The median follow-up was 24.1 months. The most frequent OMD states were metachronous oligorecurrence (23.6%) and induced oligoprogression (18.7%). Induced OMD patients had significantly shorter median OS (28.1 months) compared with…

  23. 26
    top 4.5%

    cGAS/cGAMP/STING signal propagation in the tumor microenvironment: Key role for myeloid cells in antitumor immunity

    Vera E. Mekers, Vera M. Kho, Marleen Ansems, Gosse J. Adema

    48 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.07.014OpenAlex

    Show abstract

    Cyclic GMP-AMP synthase (cGAS), second messenger 2'3'-cyclic GMP-AMP (cGAMP) and stimulator of interferon genes (STING) are fundamental for sensing cytoplasmic double stranded DNA. Radiotherapy treatment induces large amounts of nuclear and mitochondrial DNA damage and results in the presence of DNA fragments in the cytoplasm, activating the cGAS/STING pathway. Triggering of the cGAS/STING pathway in the tumor microenvironment (TME) results in the production of type I interferons (IFNs). Type I IFNs are crucial for an effective antitumor defense, with myeloid cells as key players. Many questions remain on how these myeloid cells are activated and in which cells (tumor versus myeloid) in the TME the signaling pathway is initiated. The significance of cGAS/STING signaling in the onco-immunology field is being recognized, emphasized by the frequent occurrence of mutations in or silencing of genes in this pathway. We here review several mechanisms of cGAS/STING signal propagation in the TME, focusing on tumor cells and myeloid cells. Cell-cell contact-dependent interactions facilitate…

  24. 27
    top 4.7%

    First experimental demonstration of VMAT combined with MLC tracking for single and multi fraction lung SBRT on an MR-linac

    Prescilla Uijtewaal, Pim Borman, Peter L. Woodhead, C Kontaxis, Sara Lyons Hackett and 3 more

    48 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.07.004OpenAlex

    Show abstract

    Background and purpose VMAT is not currently available on MR-linacs but could maximize plan conformality. To mitigate respiration without compromising delivery efficiency, MRI-guided MLC tumour tracking was recently developed for the 1.5 T Unity MR-linac (Elekta AB, Stockholm, Sweden) in combination with IMRT. Here, we provide a first experimental demonstration of VMAT + MLC tracking for several lung SBRT indications. Materials and methods We created central patient and phantom VMAT plans (8 × 7.5 Gy, 2 arcs) and we created peripheral phantom plans (3 × 18 & 1 × 34 Gy, 4 arcs). A motion phantom mimicked subject-recorded respiratory motion ( A ‾ =11 mm, f ‾ =0.33 Hz, drift ‾ =0.3 mm/min). This was monitored using 2D-cine MRI at 4 Hz to continuously realign the beam with the target. VMAT + MLC tracking performance was evaluated using 2D film dosimetry and a novel motion-encoded and time-resolved pseudo-3D dosimetry approach. Results We found an MLC leaf and jaw end-to-end latency of 328.05( ± 3.78) ms and 317.33( ± 4.64) ms, which was mitigated by a predictor. The VMAT plans required…

  25. 28
    top 4.8%

    Patient-specific daily updated deep learning auto-segmentation for MRI-guided adaptive radiotherapy

    Zhenjiang Li, Wei Zhang, Baosheng Li, Jian Zhu, Yinglin Peng and 4 more

    47 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.radonc.2022.11.004OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: Deep Learning (DL) technique has shown great potential but still has limited success in online contouring for MR-guided adaptive radiotherapy (MRgART). This study proposed a patient-specific DL auto-segmentation (DLAS) strategy using the patient's previous images and contours to update the model and improve segmentation accuracy and efficiency for MRgART. METHODS AND MATERIALS: A prototype model was trained for each patient using the first set of MRI and corresponding contours as inputs. The patient-specific model was updated after each fraction with all the available fractional MRIs/contours, and then used to predict the segmentation for the next fraction. During model training, a variant was fitted under consistency constraints, limiting the differences in the volume, length and centroid between the predictions for the latest MRI within a reasonable range. The model performance was evaluated for both organ-at-risks and tumors auto-segmentation for a total of 6 abdominal/pelvic cases (each with at least 8 sets of MRIs/contours) underwent MRgART through Dice…

  26. 29
    top 5%

    FLASH radiotherapy treatment planning and models for electron beams

    Mahbubur Ronny Rahman, Antonio Trigilio, Gaia Franciosini, Raphaël Moeckli, Rongxiao Zhang and 1 more

    46 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.radonc.2022.08.009OpenAlex

    Show abstract

    The FLASH effect designates normal tissue sparing at ultra-high dose rate (UHDR, >40 Gy/s) compared to conventional dose rate (∼0.1 Gy/s) irradiation while maintaining tumour control and has the potential to improve the therapeutic ratio of radiotherapy (RT). UHDR high-energy electron (HEE, 4-20 MeV) beams are currently a mainstay for investigating the clinical potential of FLASH RT for superficial tumours. In the future very-high energy electron (VHEE, 50-250 MeV) UHDR beams may be used to treat deep-seated tumours. UHDR HEE treatment planning focused at its initial stage on accurate dosimetric modelling of converted and dedicated UHDR electron RT devices for the clinical transfer of FLASH RT. VHEE treatment planning demonstrated promising dosimetric performance compared to clinical photon RT techniques in silico and was used to evaluate and optimise the design of novel VHEE RT devices. Multiple metrics and models have been proposed for a quantitative description of the FLASH effect in treatment planning, but an improved experimental characterization and understanding of the FLASH…

  27. 30
    top 5.2%

    Treatment planning considerations for the development of FLASH proton therapy

    Bethany Rothwell, Matthew Lowe, Erik Tranéus, Miriam Krieger, Jan Schuemann

    46 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.08.003OpenAlex

    Show abstract

    With increasing focus on the translation of the observed FLASH effect into clinical practice, this paper presents treatment planning considerations for its development using proton therapy. Potential requirements to induce a FLASH effect are discussed along with the properties of existing proton therapy delivery systems and the changes in planning and delivery approaches required to satisfy these prerequisites. For the exploration of treatment planning approaches for FLASH, developments in treatment planning systems are needed. Flexibility in adapting to new information will be important in such an evolving area. Variations in definitions, threshold values and assumptions can make it difficult to compare different published studies and to interpret previous studies in the context of new information. Together with the fact that much is left to be understood about the underlying mechanism behind the FLASH effect, a systematic and comprehensive approach to information storage is encouraged. Collecting and retaining more detailed information on planned and realised dose delivery as well…

  28. 31
    top 5.4%

    Dose prediction via distance-guided deep learning: Initial development for nasopharyngeal carcinoma radiotherapy

    Meiyan Yue, Xiaoguang Xue, Zhanyu Wang, Ricardo Lewis Lambo, Wei Zhao and 3 more

    46 citationsdoi:10.1016/j.radonc.2022.03.012OpenAlex

  29. 32
    top 5.5%

    HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results – Interim analysis

    Santam Chakraborty, Sanjoy Chatterjee, Selvamani Backianathan, Punita Lal, Subhash Chandra Gupta and 16 more

    45 citationsdoi:10.1016/j.radonc.2022.07.003OpenAlex

  30. 33
    top 5.7%

    Volume matters: Breast induration is associated with irradiated breast volume in the Danish Breast Cancer Group phase III randomized Partial Breast Irradiation trial

    Mette Skovhus Thomsen, Jan Alsner, Hanne Melgaard Nielsen, Erik Hugger Jakobsen, Mette Holck Nielsen and 9 more

    44 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.09.024OpenAlex

    Show abstract

    PURPOSE: The relation between breast induration grade 2-3 at 3 years after radiation therapy and irradiated breast volume was investigated for patients in the Danish Breast Cancer Group (DBCG) Partial Breast Irradiation (PBI) trial. METHODS Treatment plan data was obtained from the Danish radiotherapy plan database. Dosimetric parameters for breast and organs at risk were determined. Breast induration data was obtained from the DBCG database. The volume of the whole breast (CTVp_breast) treated to various dose levels was determined for treatment plans in both arms. Logistic regression was used to assess the frequency of induration on breast volume irradiated to ≥40 Gy. RESULTS PBI and WBI was given to 433 and 432 patients, respectively. Median and interquartile ranges (IQR) for CTVp_breast were 710 mL (467-963 mL; PBI) and 666 mL (443-1012 mL; WBI) (p = 0.98). Median and IQR for CTVp_breast treated to ≥40 Gy was 24.9% (18.6-32.6%; PBI) and 59.8% (53.6-68.5%; WBI). Grade 2-3 induration was observed in 5% (PBI) and 10% (WBI) of the patients. A dose-response relationship was…

  31. 34
    top 5.9%

    Plan quality assessment in clinical practice: Results of the 2020 ESTRO survey on plan complexity and robustness

    Laura Patricia Kaplan, Lorenzo Placidi, Anna Bäck, Richard A. M. Canters, Mohammad Hussein and 7 more

    44 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.06.005OpenAlex

    Show abstract

    PURPOSE: Plan complexity and robustness are two essential aspects of treatment plan quality but there is a great variability in their management in clinical practice. This study reports the results of the 2020 ESTRO survey on plan complexity and robustness to identify needs and guide future discussions and consensus. METHODS: A survey was distributed online to ESTRO members. Plan complexity was defined as the modulation of machine parameters and increased uncertainty in dose calculation and delivery. Robustness was defined as a dose distribution's sensitivity towards errors stemming from treatment uncertainties, patient setup, or anatomical changes. RESULTS: A total of 126 radiotherapy centres from 33 countries participated, 95 of them (75%) from Europe and Central Asia. The majority controlled and evaluated plan complexity using monitor units (56 centres) and aperture shapes (38 centres). To control robustness, 98 (97% of question responses) photon and 5 (50%) proton centres used PTV margins for plan optimization while 75 (94%) and 5 (50%), respectively, used margins for plan…

  32. 35
    top 6%

    Online adaptive radiotherapy of anal cancer: Normal tissue sparing, target propagation methods, and first clinical experience

    Lina M. Åström, C.F. Behrens, Katrine Smedegaard Storm, Patrik Sibolt, Eva Serup‐Hansen

    43 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.09.015OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: Online adaptive radiotherapy (oART) potentially spares OARs as PTV margins are reduced. This study evaluates dosimetric benefits, compared to standard non-adaptive radiotherapy (non-ART), target propagation methods, and first clinical treatments of CBCT-guided oART of anal cancer. MATERIALS AND METHODS: Treatment plans with standard non-ART and reduced oART PTV margins were retrospectively generated for 23 consecutive patients with anal cancer. For five patients randomly selected among the 23 patients, weekly CBCT-guided oART sessions were simulated, where the targets were either deformed or rigidly propagated. Preferred target propagation method and dose to OARs were evaluated. Ten consecutive patients with anal cancer were treated with CBCT-guided oART. Target propagation methods and oART procedure time were evaluated. RESULTS: of 16.1%. Corresponding values for the simulated sessions were 7.5% and 27.1%. In the simulated sessions, 35% of all targets were deformed while 65% were rigidly propagated. Manual editing and rigid propagation were necessary to…

  33. 36
    top 6.2%

    A deep learning approach to generate synthetic CT in low field MR-guided radiotherapy for lung cases

    Jacopo Lenkowicz, Claudio Votta, Matteo Nardini, Flaviovincenzo Quaranta, Francesco Catucci and 11 more

    43 citationsdoi:10.1016/j.radonc.2022.08.028OpenAlex

  34. 37
    top 6.4%

    Clinical use and future requirements of relative biological effectiveness: Survey among all European proton therapy centres

    Lena Heuchel, Christian Hahn, Jörg Pawelke, Brita Singers Sørensen, Manjit K. Dosanjh and 1 more

    43 citationsOpen accessdoi:10.1016/j.radonc.2022.05.015OpenAlex

  35. 38
    top 6.6%

    Feasibility of clinical target volume reduction for glioblastoma treated with standard chemoradiation based on patterns of failure analysis

    Giuseppe Caracciolo Minniti, Paolo Tini, Martina Giraffa, Luca Capone, Giorgio Hamid Raza and 6 more

    42 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.radonc.2022.11.024OpenAlex

  36. 39
    top 6.7%

    SBRT focal dose intensification using an MR-Linac adaptive planning for intermediate-risk prostate cancer: An analysis of the dosimetric impact of intra-fractional organ changes

    Victoria Sarah Brennan, Sarah Burleson, Caroline E. Kostrzewa, Paola Godoy Scripes, Ergys Subashi and 3 more

    41 citationsdoi:10.1016/j.radonc.2022.109441OpenAlex

  37. 40
    top 6.9%

    Changes in Radical Levels as a Cause for the FLASH effect: Impact of beam structure parameters at ultra-high dose rates on oxygen depletion in water

    Jeannette Jansen, Elke Beyreuther, Daniel García-Calderón, Leonhard Karsch, Jan Knoll and 3 more

    41 citationsdoi:10.1016/j.radonc.2022.08.024OpenAlex

  38. 42
    top 7.2%

    Deviation from consensus contouring guidelines predicts inferior local control after spine stereotactic body radiotherapy

    Xuguang Chen, Michael C. LeCompte, Chengcheng Gui, Ellen Huang, Majid Khan and 5 more

    39 citationsdoi:10.1016/j.radonc.2022.05.035OpenAlex

  39. 43
    top 7.4%

    Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy

    Ditte Sloth Møller, Christina Maria Lutz, Azza Ahmed Khalil, Markus L. Alber, Marianne Ingerslev Holt and 6 more

    39 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.01.039OpenAlex

    Show abstract

    Introduction Tumor match and adaptive radiotherapy based on on-treatment imaging increases the precision of RT. This allows a reduction of treatment volume and, consequently, of the dose to organs at risk. We investigate the clinical benefits of tumor match and adaptive radiotherapy for a cohort of non-small cell lung cancer patients (NSCLC). Methods In 2013, tumor match and adaptive radiotherapy based on daily cone-beam CT scans was introduced to ensure adaption of the radiotherapy treatment plan for all patients with significant anatomical changes during radiotherapy. Before 2013, the daily cone-beam CT scans were matched on the vertebra and anatomical changes were not evaluated systematically. To estimate the effect of tumor match and adaptive radiotherapy, 439 consecutive NSCLC patients treated with definitive chemo-radiotherapy (50–66 Gy/25–33 fractions, 2010–2018) were investigated retrospectively. They were split in two groups, pre-ART (before tumor match and adaptive radiotherapy, 184 patients), and ART (after tumor match and adaptive radiotherapy, 255 patients) and compared…

  40. 44
    top 7.6%

    ESTRO ACROP and SIOPE recommendations for myeloablative Total Body Irradiation in children

    Bianca A.W. Hoeben, Montserrat Pazos, Enrica Seravalli, Mirjam E. Bosman, Christoph Losert and 20 more

    38 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.05.027OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: Myeloablative Total Body Irradiation (TBI) is an important modality in conditioning for allogeneic hematopoietic stem cell transplantation (HSCT), especially in children with high-risk acute lymphoblastic leukemia (ALL). TBI practices are heterogeneous and institution-specific. Since TBI is associated with multiple late adverse effects, recommendations may help to standardize practices and improve the outcome versus toxicity ratio for children. MATERIAL AND METHODS: The European Society for Paediatric Oncology (SIOPE) Radiotherapy TBI Working Group together with ESTRO experts conducted a literature search and evaluation regarding myeloablative TBI techniques and toxicities in children. Findings were discussed in bimonthly virtual meetings and consensus recommendations were established. RESULTS: Myeloablative TBI in HSCT conditioning is mostly performed for high-risk ALL patients or patients with recurring hematologic malignancies. TBI is discouraged in children <3-4 years old because of increased toxicity risk. Publications regarding TBI are mostly…

  41. 45
    top 7.8%

    Clinical application of a sub-fractionation workflow for intrafraction re-planning during prostate radiotherapy treatment on a 1.5 Tesla MR-Linac: A practical method to mitigate intrafraction motion

    T. Willigenburg, Cornel Zachiu, G.H. Bol, Eline N. de Groot-van Breugel, J J W Lagendijk and 3 more

    37 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.09.004OpenAlex

    Show abstract

    BACKGROUND: Intrafraction motion during radiotherapy limits margin reduction and dose escalation. Magnetic resonance (MR)-guided linear accelerators (MR-Linac) have emphasised this issue by enabling intrafraction imaging. We present and clinically apply a new workflow to counteract systematic intrafraction motion during MR-guided stereotactic body radiotherapy (SBRT). MATERIALS AND METHODS: With the sub-fractionation workflow, the daily dose is delivered in multiple sequential parts (sub-fractions), each adapted to the latest anatomy. As each sub-fractionation treatment plan complies with the dose constraints, no online dose accumulation is required. Imaging and treatment planning are executed in parallel with dose delivery to minimise dead time, enabling an efficient workflow. The workflow was implemented on a 1.5 T MR-Linac and applied in 15 prostate cancer (PCa) patients treated with 5 × 7.25 Gy in two sub-fractions of 3.625 Gy (10 × 3.625 Gy in total). Intrafraction clinical target volume (CTV) motion was determined and compared to a workflow with single-plan delivery.…

  42. 46
    top 7.9%

    Repeatability of diffusion-weighted magnetic resonance imaging in head and neck cancer at a 1.5 T MR-Linac

    Jonas Habrich, Simon Boeke, Marcel Nachbar, Konstantin Nikolaou, Fritz Schick and 3 more

    37 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.07.020OpenAlex

    Show abstract

    Background and purpose Functional information acquired through diffusion-weighted magnetic resonance imaging (DW-MRI) may be beneficial for personalized head and neck cancer (HNC) radiotherapy. Technical validation is required before DW-MRI based radiotherapy interventions can be realized clinically. The aim of this study was to assess the repeatability of apparent diffusion coefficients (ADC) derived from DW-MRI in HNC using echo-planar imaging (EPI) on a 1.5 T MR-Linac. Material and methods A total of eleven HNC patients underwent test/retest DW-MRI scans at least once per week during fractionated radiotherapy at the MR-Linac. An EPI DW-MRI test scan (b = 0, 150, 500 s/mm 2 ) was acquired before the start of adaptive MR-guided radiotherapy in addition to an identical retest scan after irradiation. Volumes-of-interest (VOI) were defined manually for parotid (PTs) and submandibular glands (SMs), gross tumor volume (GTV) and lymph nodes (LNs). Mean ADC was calculated for all VOI in all test/retest scans. Absolute/relative repeatability coefficients (RCs/relRCs) as well as intraclass…

  43. 47
    top 8.1%

    Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era

    Neal S. McCall, Hamilton S. McGinnis, James Robert Janopaul-Naylor, Aparna Hemant Kesarwala, Sibo Tian and 8 more

    37 citationsdoi:10.1016/j.radonc.2022.07.015OpenAlex

  44. 48
    top 8.3%
  45. 49
    top 8.4%

    Impact of sarcopenia on acute radiation-induced toxicity in head and neck cancer patients

    Eleftheria Karavolia, Maria I. van Rijn–Dekker, L. Van den Bosch, Johanna G.M. van den Hoek, Edwin Oldehinkel and 7 more

    35 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.03.009OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: Sarcopenia is related to late radiation-induced toxicities and worse survival in head and neck cancer (HNC) patients. This study tested the hypothesis that sarcopenia improves the performance of current normal tissue complication probability (NTCP) models of radiation-induced acute toxicity in HNC patients. MATERIAL/METHODS: This was a retrospective analysis in a prospective cohort of HNC patients treated from January 2007 to December 2018 with (chemo)radiotherapy. Planning CT scans were used for evaluating skeletal muscle mass. Characteristics of sarcopenic and non-sarcopenic patients were compared. The impact of sarcopenia was analysed by adding sarcopenia to the linear predictors of current NTCP models predicting physician- and patient-rated acute toxicities. RESULTS: The cut-off values of sarcopenia in the study population (n = 977) were established at skeletal muscle index < 42.0 cm2/m2 (men) and < 31.2 cm2/m2 (women), corresponding to the lowest sex-specific quartile. Compared to non-sarcopenic patients, sarcopenic patients were more frequently smokers…

  46. 50
    top 8.6%

    An online adaptive plan library approach for intensity modulated proton therapy for head and neck cancer

    Michelle Oud, Sebastiaan Breedveld, Marta Krystyna Giżyńska, Michiel Kroesen, Stefan A.J. Hutschemaekers and 5 more

    34 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.09.011OpenAlex

    Show abstract

    Background and purpose In intensity modulated proton therapy (IMPT), the impact of setup errors and anatomical changes is commonly mitigated by robust optimization with population-based setup robustness (SR) settings and offline replanning. In this study we propose and evaluate an alternative approach based on daily plan selection from patient-specific pre-treatment established plan libraries (PLs). Clinical implementation of the PL strategy would be rather straightforward compared to daily online re-planning. Materials and methods For 15 head-and-neck cancer patients, the planning CT was used to generate a PL with 5 plans, robustly optimized for increasing SR: 0, 1, 2, 3, 5 mm, and 3% range robustness. Repeat CTs (rCTs) and realistic setup and range uncertainty distributions were used for simulation of treatment courses for the PL approach, treatments with fixed SR (fSR 3 ) and a trigger-based offline adaptive schedule for 3 mm SR (fSR 3 OfA). Daily plan selection in the PL approach was based only on recomputed dose to the CTV on the rCT. Results Compared to using fSR 3 and fSR 3…

How to read this list

The cohort is every article, review and book chapter OpenAlex attributes to Radiotherapy and Oncology with publication year 2022, excluding retracted works and paratext such as editorials and errata. The top 50 by citation count are listed; the percentile is the rank divided by the cohort size. 26 of the 50 entries have an abstract in OpenAlex. Counts were read on 29 October 2026 and will not be updated on this page, so a quoted rank stays verifiable. Full rules on the methodology page.

Other journals, same idea

Work with these 25 papers in Kahubi

  • The papers land in your library with their DOIs
  • Ask anything across all of them, with citations
  • Draft a literature review from the same sources

Free plan, no card. Your files stay private unless you share them.

Reading several of these?

Kahubi reads papers with you, keeps every citation traceable and drafts with sources you can check. Free plan, no card.